The South African government has committed to investing $72 million in the rollout of Lenacapavir, an innovative drug for HIV prevention, in an ambitious effort to reduce the number of new infections and combat the world’s largest HIV epidemic.
South African President Cyril Ramaphosa recently announced on his social media account the launch of this large-scale initiative, aimed at making Lenacapavir—a long-acting injectable drug considered revolutionary in HIV prevention—widely available.
Describing the funding as a “catalytic investment,” Ramaphosa stated that the partnership reflects a principle South Africa has consistently championed: life-saving medicines should never be a privilege reserved for a few, but rather accessible to all who need them.
To understand the importance of this initiative, it is important to explain how the drug works. Lenacapavir is the first drug of its class, acting as a viral capsid inhibitor—that is, it blocks the virus’s outer shell, preventing it from multiplying and invading human cells.
Because the drug is released slowly into the body, it only needs to be administered via injection twice a year. In large-scale international clinical trials, including studies conducted in South Africa and Uganda, it has demonstrated nearly 100% efficacy.
By replacing the need to take a daily preventive pill with a simple injection every six months, the treatment significantly reduces the common problem of missed doses.
Funding and distribution in the first phase
The announcement marks a turning point for South African public health, as the country has the largest number of people living with HIV in the world.
The program’s implementation, budgeted at $72 million, will be funded by the South African government and international partners, including the Global Fund and the Children’s Investment Fund Foundation (CIFF).
The first phase is set to launch in 360 public health facilities across 24 districts with high disease prevalence. The government’s goal is to reach approximately one million people by the end of 2027, prioritizing high-risk groups such as adolescent girls, young women, and pregnant women.
High Costs and a Commitment to Local Production
Although the initiative has been hailed by health experts as a historic milestone, its implementation faces logistical and economic challenges.
Since the original version of the drug, produced by the U.S. pharmaceutical company Gilead, is very expensive, South Africa’s long-term strategy relies heavily on a voluntary licensing agreement.
This agreement is expected to allow more affordable generic versions to enter the domestic market by 2027, in line with a continental effort to ensure that 60% of medical products used in Africa are manufactured locally by 2040.
Source: Africa Business Insider
